Weekly Analysts’ Ratings Updates for Dyne Therapeutics (DYN)

Several analysts have recently updated their ratings and price targets for Dyne Therapeutics (NASDAQ: DYN):

• 3/7/2025 – Dyne Therapeutics is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $50.00 price target on the stock.
• 2/28/2025 – Dyne Therapeutics had its price target lowered by analysts at Piper Sandler from $53.00 to $48.00. They now have an “overweight” rating on the stock.
• 2/28/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.
• 2/28/2025 – Dyne Therapeutics had its price target lowered by analysts at HC Wainwright from $55.00 to $46.00. They now have a “buy” rating on the stock.
• 1/24/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim.
• 1/14/2025 – Dyne Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $45.00 price target on the stock.
• 1/10/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.
• 1/10/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.

Dyne Therapeutics Stock Performance

DYN traded up $0.33 during mid-day trading on Tuesday, reaching $11.83. The stock had a trading volume of 1,148,935 shares, compared to its average volume of 2,178,542. The stock has a market capitalization of $1.34 billion, a P/E ratio of -3.32 and a beta of 1.11. Dyne Therapeutics, Inc. has a 52 week low of $11.18 and a 52 week high of $47.45. The firm’s fifty day simple moving average is $15.56 and its two-hundred day simple moving average is $26.06.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. As a group, analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,387 shares of company stock valued at $142,789 over the last 90 days. 20.77% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently made changes to their positions in DYN. State of New Jersey Common Pension Fund D bought a new stake in Dyne Therapeutics in the third quarter valued at approximately $1,588,000. Jennison Associates LLC lifted its holdings in Dyne Therapeutics by 1.5% during the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after purchasing an additional 19,730 shares during the last quarter. abrdn plc bought a new position in Dyne Therapeutics during the fourth quarter worth $608,000. RA Capital Management L.P. increased its holdings in shares of Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after purchasing an additional 331,940 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Dyne Therapeutics by 4.8% in the third quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock valued at $66,802,000 after purchasing an additional 84,760 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.